Easton Pharmaceuticals Reaches Manufacturing Agreement For Company’s OTC Products in North America and Latin AmericaPress release August 13, 2014
Advances Timetable for OTC Product Launch
Easton Pharmaceuticals Announces It Has Reached Manufacturing Agreement For Company’s OTC Products; Advances Timetable For Product Launch
August 13, 2014 (8am) - Easton Pharmaceuticals (OTC:EAPH) announces they have sourced out and come to terms with a manufacturing partner for the North American Market, nears finalizing a manufacturing Agreement for Latin American market and advances timetable towards VIORRA and other OTC product launches.
Easton Pharmaceuticals has sourced out and come to terms with a GMP certified manufacturer located in Toronto, Canada who will supply the U.S. and Canadian markets. Pricing is on par with Mexican manufacturers, but the company believes quality control can be better managed in local jurisdictions. Final agreements are being finalized with the manufacturing company who have manufactured and packaged dozens of products for various company’s in North America. Easton has in addition entered into negotiations with other companies for distribution of its OTC products and is close to finalizing an agreement which will allow for the marketing and sale of the company’s products to commence in the near term. A formal announcement on the North American manufacturing partner and what we believe to be significant developments with our OTC products is anticipated sometime within the next 2 to 3 weeks.
It is expected that the Latin American efforts, namely the country of Mexico will still have its manufacturing realized in Mexico. BMV Medica, and Dr. Daniel Bagi, a consultant for Easton Pharmaceuticals have reached an agreement in principle with a manufacturer in Mexico. Initial discussions with another FDA approved manufacturer in Mexico were canceled due to pricing dis-agreements with the company. Easton will be using BMV Medica for its distribution of products in Mexico and Latin American markets
Carla Pepe, CEO of Easton Pharmaceuticals, commented “ Although the launch of Viorra and our other OTC products have taken a bit of a back seat to our medical marijuana initiatives, much of the ground work has been laid out where the company feels it should now move towards manufacturing, marketing and distribution in a diligent and expeditious manner. We anticipate positive announcements will soon be forthcoming that will demonstrate our commitment to our OTC products in conjunction with our medical marijuana initiatives.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues geared towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
EAPH Otc:eaph Medical Marijuana Easton pharmaceuticals Viorra Pharmaceutical